胃癌腹膜转移的分子生物学和免疫学研究。

IF 3 4区医学 Q1 Medicine Translational gastroenterology and hepatology Pub Date : 2020-10-05 eCollection Date: 2020-01-01 DOI:10.21037/tgh.2020.02.08

Xiaodan Yao, Jaffer A Ajani, Shumei Song

{"title":"胃癌腹膜转移的分子生物学和免疫学研究。","authors":"Xiaodan Yao, Jaffer A Ajani, Shumei Song","doi":"10.21037/tgh.2020.02.08","DOIUrl":null,"url":null,"abstract":"Peritoneal metastases occur in 55-60% of patients with gastric cancer (GC) and are associated with a 2% 5-year overall survival rate. There are limited treatment options for these patients, and no targeted therapy or immunotherapy is available. Rational therapeutic targets remain to be found. In this review, we present the published literature and our own recent experience in molecular biology to identify important molecules and signaling pathways as well as cellular immunity involved in the peritoneal metastasis of GC. We also suggest potential novel strategies for improving the outcomes of GC patients with peritoneal metastasis.","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"5 ","pages":"57"},"PeriodicalIF":3.0000,"publicationDate":"2020-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/tgh.2020.02.08","citationCount":"12","resultStr":"{\"title\":\"Molecular biology and immunology of gastric cancer peritoneal metastasis.\",\"authors\":\"Xiaodan Yao, Jaffer A Ajani, Shumei Song\",\"doi\":\"10.21037/tgh.2020.02.08\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Peritoneal metastases occur in 55-60% of patients with gastric cancer (GC) and are associated with a 2% 5-year overall survival rate. There are limited treatment options for these patients, and no targeted therapy or immunotherapy is available. Rational therapeutic targets remain to be found. In this review, we present the published literature and our own recent experience in molecular biology to identify important molecules and signaling pathways as well as cellular immunity involved in the peritoneal metastasis of GC. We also suggest potential novel strategies for improving the outcomes of GC patients with peritoneal metastasis.\",\"PeriodicalId\":23267,\"journal\":{\"name\":\"Translational gastroenterology and hepatology\",\"volume\":\"5 \",\"pages\":\"57\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2020-10-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.21037/tgh.2020.02.08\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational gastroenterology and hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tgh.2020.02.08\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational gastroenterology and hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tgh.2020.02.08","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 12

摘要

55-60%的胃癌(GC)患者发生腹膜转移，5年总生存率为2%。这些患者的治疗选择有限，没有靶向治疗或免疫治疗可用。合理的治疗靶点仍有待发现。在这篇综述中，我们介绍了已发表的文献和我们自己最近在分子生物学方面的经验，以确定胃癌腹膜转移的重要分子和信号通路以及细胞免疫。我们还提出了改善胃癌腹膜转移患者预后的潜在新策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Molecular biology and immunology of gastric cancer peritoneal metastasis.

Peritoneal metastases occur in 55-60% of patients with gastric cancer (GC) and are associated with a 2% 5-year overall survival rate. There are limited treatment options for these patients, and no targeted therapy or immunotherapy is available. Rational therapeutic targets remain to be found. In this review, we present the published literature and our own recent experience in molecular biology to identify important molecules and signaling pathways as well as cellular immunity involved in the peritoneal metastasis of GC. We also suggest potential novel strategies for improving the outcomes of GC patients with peritoneal metastasis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Translational gastroenterology and hepatology Medicine-Gastroenterology

CiteScore

8.20

自引率

0.00%

发文量

期刊介绍： Translational Gastroenterology and Hepatology (Transl Gastroenterol Hepatol; TGH; Online ISSN 2415-1289) is an open-access, peer-reviewed online journal that focuses on cutting-edge findings in the field of translational research in gastroenterology and hepatology and provides current and practical information on diagnosis, prevention and clinical investigations of gastrointestinal, pancreas, gallbladder and hepatic diseases. Specific areas of interest include, but not limited to, multimodality therapy, biomarkers, imaging, biology, pathology, and technical advances related to gastrointestinal and hepatic diseases. Contributions pertinent to gastroenterology and hepatology are also included from related fields such as nutrition, surgery, public health, human genetics, basic sciences, education, sociology, and nursing.